HIV-infected people and pregnant women are at risk of developing severe pneumococcal disease.
The purpose of this study is to compare the safety and immune response to two pneumococcal
vaccines in HIV-infected pregnant women.
Biological: PPV-23 Vaccine
Biological: PCV-13 Vaccine
Biological: Placebo Vaccine
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01443117
Ages eligible for Study
13 Years to 39 Years
Genders eligible for Study
Accepts Healthy Volunteers
All locations for NCT01443117
View full eligibility
Tris trial is registered with FDA with number: NCT01443117. The sponsor of the trial is National Institute of Allergy and Infectious Diseases (NIAID) and it is looking for 0 volunteers for the current phase.
Official trial title: Administration of Polysaccharide or Conjugated Pneumococcal Vaccines to HIV-Infected Pregnant Women: Safety and Magnitude, Persistence, and Transplacental Transfer of Vaccine-Serotype Pneumococcal Anti-Capsular Antibodies
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.